Brian T Fife1, Tijana Martinov2,3, Christopher G Tucker4, Alexander J Dwyer4. 1. Department of Medicine, Center for Immunology, University of Minnesota Medical School, 2101 6th St SE, Wallin Medical Biosciences Building, 3-146, Minneapolis, MN, 55455, USA. bfife@umn.edu. 2. Department of Medicine, Center for Immunology, University of Minnesota Medical School, 2101 6th St SE, Wallin Medical Biosciences Building, 3-146, Minneapolis, MN, 55455, USA. tmartino@fredhutch.org. 3. Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, Thomas Building, D3-100, Seattle, WA, 98109, USA. tmartino@fredhutch.org. 4. Department of Medicine, Center for Immunology, University of Minnesota Medical School, 2101 6th St SE, Wallin Medical Biosciences Building, 3-146, Minneapolis, MN, 55455, USA.
Abstract
PURPOSE OF REVIEW: Programmed death-1 (PD-1) is an inhibitory receptor that controls T and B cell proliferation and function through interacting with its ligand PD-L1 or PD-L2. PD-1/PD-L1 blockade reboots anti-tumor immunity and is currently used to treat > 15 different types of cancer. However, the response rate is not at 100% and some patients relapse. Importantly, up to 37% of patients treated with PD-1/PD-L1 blocking antibodies develop immune-related adverse events, including overt autoimmunity, such as type 1 diabetes (T1D). Herein, we discuss the role of PD-1, PD-L1, and PD-L2 signaling in pre-clinical models of T1D, including recent work from our laboratory. RECENT FINDINGS: We highlight ongoing efforts to harness PD-1/PD-L1 signaling and treat autoimmunity. We also evaluate studies aimed at defining biomarkers that could reliably predict the development of immune-related adverse events after clinical PD-1/PD-L1 blockade. With increasing use of PD-1 blockade in the clinic, onset of autoimmunity is a growing health concern. In this review, we discuss what is known about the role of PD-1 pathway signaling in T1D and comment on ongoing efforts to identify patients at risk of T1D development after PD-1 pathway blockade.
PURPOSE OF REVIEW: Programmed death-1 (PD-1) is an inhibitory receptor that controls T and B cell proliferation and function through interacting with its ligand PD-L1 or PD-L2. PD-1/PD-L1 blockade reboots anti-tumor immunity and is currently used to treat > 15 different types of cancer. However, the response rate is not at 100% and some patients relapse. Importantly, up to 37% of patients treated with PD-1/PD-L1 blocking antibodies develop immune-related adverse events, including overt autoimmunity, such as type 1 diabetes (T1D). Herein, we discuss the role of PD-1, PD-L1, and PD-L2 signaling in pre-clinical models of T1D, including recent work from our laboratory. RECENT FINDINGS: We highlight ongoing efforts to harness PD-1/PD-L1 signaling and treat autoimmunity. We also evaluate studies aimed at defining biomarkers that could reliably predict the development of immune-related adverse events after clinical PD-1/PD-L1 blockade. With increasing use of PD-1 blockade in the clinic, onset of autoimmunity is a growing health concern. In this review, we discuss what is known about the role of PD-1 pathway signaling in T1D and comment on ongoing efforts to identify patients at risk of T1D development after PD-1 pathway blockade.
Authors: H Nishimura; T Okazaki; Y Tanaka; K Nakatani; M Hara; A Matsumori; S Sasayama; A Mizoguchi; H Hiai; N Minato; T Honjo Journal: Science Date: 2001-01-12 Impact factor: 47.728
Authors: Daniel L Barber; E John Wherry; David Masopust; Baogong Zhu; James P Allison; Arlene H Sharpe; Gordon J Freeman; Rafi Ahmed Journal: Nature Date: 2005-12-28 Impact factor: 49.962
Authors: Giorgia Rota; Charlène Niogret; Anh Thu Dang; Cristina Ramon Barros; Nicolas Pierre Fonta; Francesca Alfei; Leonor Morgado; Dietmar Zehn; Walter Birchmeier; Eric Vivier; Greta Guarda Journal: Cell Rep Date: 2018-04-03 Impact factor: 9.423
Authors: S Asad; S Fawwaz; P Nikamo; C Törn; M Landin-Olsson; A Lernmark; M Alarcón-Riquelme; I Kockum Journal: Diabet Med Date: 2007-12 Impact factor: 4.359
Authors: Maikel L Colli; Jessica L E Hill; Laura Marroquí; Jessica Chaffey; Reinaldo S Dos Santos; Pia Leete; Alexandra Coomans de Brachène; Flavia M M Paula; Anne Op de Beeck; Angela Castela; Lorella Marselli; Lars Krogvold; Knut Dahl-Jorgensen; Piero Marchetti; Noel G Morgan; Sarah J Richardson; Décio L Eizirik Journal: EBioMedicine Date: 2018-09-27 Impact factor: 8.143
Authors: Laura Strauss; Mohamed A A Mahmoud; Jessica D Weaver; Natalia M Tijaro-Ovalle; Anthos Christofides; Qi Wang; Rinku Pal; Min Yuan; John Asara; Nikolaos Patsoukis; Vassiliki A Boussiotis Journal: Sci Immunol Date: 2020-01-03